

Non-significant influence between aerobic and anaerobic sample transport materials on gut (fecal) microbiota in healthy and fat-metabolic disorder Thai adults

Naruemon Tunsakul¹, Lampet Wongsaraj², Kantima Janchot³, Krit Pongpirul³, Naraporn Somboonna^{Corresp. 2, 4, 5}

¹ Program in Biotechnology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand

² Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand

³ Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

⁴ Microbiome Research Unit for Probiotics in Food and Cosmetics, Chulalongkorn University, Bangkok, Thailand

⁵ Omics Sciences and Bioinformatics Center, Faculty of Science, Chulalongkorn University, Bangkok, Thailand

Corresponding Author: Naraporn Somboonna

Email address: Naraporn.S@chula.ac.th

Background. The appropriate sample handling for human fecal microbiota studies is essential to prevent changes in bacterial composition and quantities that could lead to misinterpretation of the data. **Methods.** This study thereby firstly identified potential effect of aerobic and anaerobic fecal sample collection and transport materials on microbiota and quantitative microbiota in healthy and fat-metabolic disorder Thai adults aged 23-43 years, utilizing metagenomics followed 16S rRNA gene sequencing and 16S rRNA gene qPCR. We analyzed taxonomic composition, alpha diversity, beta diversity, bacterial quantification, Pearson's correlation with clinical factors for fat-metabolic disorder, and the microbial community and species potential metabolic functions. **Results.** Our study successfully obtained microbiota results in percent and quantitative compositions. The quality sequences in each sample had > 99% Good's coverage index, relatively plateau rarefaction curve, and alpha diversity indices that showed no statistical difference in percent and quantitative microbiota OTU richness and evenness, between aerobic and anaerobic sample transport materials. Obligate and facultative anaerobic species were analyzed and also showed no significantly different. Supportively, the beta diversity analysis by non-metric multidimensional scale (NMDS) could not distinguish microbiota community structures between aerobic and anaerobic sample transport groups ($P = 0.864$); yet could distinguish microbiota community structures between healthy and fat-metabolic disorder groups ($P = 0.049$), along the Pearson's correlated clinical parameters (i.e. age, liver stiffness, GGT, BMI, and TC), the significant associated bacterial species, and their microbial metabolic functions. For examples, genera such as *Ruminococcus* and *Biofidobacterium* were exhibited in healthy human gut and provided

functions in metabolisms of cofactors and vitamins, biosynthesis of secondary metabolites against gut bacterial pathogens, energy metabolisms, digestive system, and carbohydrate metabolism; and these characteristics were also predicted as healthy subject markers with the significant LEfSe scores. In conclusion, this study demonstrated that short term aerobic sample collection and transport (< 48 hours) did not statistically affected the microbiota and quantitative microbiota analyses in alpha and beta diversity measurements. The study also demonstrated that the short term aerobic sample collection and transport still allowed fecal microbiota differentiations between healthy and fat-metabolic disorder subjects, similar with anaerobic sample collection and transport. Moreover, the microbiota related metabolic function potentials and bacterial species biomarkers in healthy and fat-metabolic disorder were suggested with statistic bioinformatics, albeit limitation of inter-individual human differences such as sex and diet patterns.

1 **Non-significant influence between aerobic and anaerobic sample transport**
2 **materials on gut (fecal) microbiota in healthy and fat-metabolic disorder Thai**
3 **adults**

4

5 **Running Title:** Aerobic & anaerobic transport microbiota

6

7 Naruemon Tunsakul¹, Lampet Wongsaroj², Kantima Janchot³, Krit Pongpirul³, and Naraporn

8 Somboonna^{2,4,5*}

9

10 ¹ Program in Biotechnology, Faculty of Science, Chulalongkorn University, Bangkok 10330,

11 Thailand

12 ² Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok 10330,

13 Thailand

14 ³ Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

15 ⁴ Microbiome Research Unit for Probiotics in Food and Cosmetics, Chulalongkorn University,

16 Bangkok 10330, Thailand

17 ⁵ Omics Sciences and Bioinformatics Center, Faculty of Science, Chulalongkorn University,

18 Bangkok 10330, Thailand

19

20 * Correspondence, Dr. Naraporn Somboonna, Department of Microbiology, Faculty of Science,

21 Chulalongkorn University, Phyathai Road, Pathumwan, Bangkok 10330, Thailand; email:

22 Naraporn.S@chula.ac.th

23

24 Email addresses:

25 NT: bn.tunsakul@gmail.com

26 LW: lwongsaroj@gmail.com

27 KJ: Kantima.janchot@gmail.com

28 KP: doctorkrit@gmail.com

29 NS: Naraporn.S@chula.ac.th

30

31 **Abstract**

32 **Background.** The appropriate sample handling for human fecal microbiota studies is essential to
33 prevent changes in bacterial composition and quantities that could lead to misinterpretation of
34 the data.

35 **Methods.** This study thereby firstly identified potential effect of aerobic and anaerobic fecal
36 sample collection and transport materials on microbiota and quantitative microbiota in healthy
37 and fat-metabolic disorder Thai adults aged 23-43 years, utilizing metagenomics followed 16S
38 rRNA gene sequencing and 16S rRNA gene qPCR. We analyzed taxonomic composition, alpha
39 diversity, beta diversity, bacterial quantification, Pearson's correlation with clinical factors for
40 fat-metabolic disorder, and the microbial community and species potential metabolic functions.

41 **Results.** Our study successfully obtained microbiota results in percent and quantitative
42 compositions. The quality sequences in each sample had > 99% Good's coverage index,
43 relatively plateau rarefaction curve, and alpha diversity indices that showed no statistical
44 difference in percent and quantitative microbiota OTU richness and evenness, between aerobic
45 and anaerobic sample transport materials. Obligate and facultative anaerobic species were

46 analyzed and also showed no significantly different. Supportively, the beta diversity analysis by
47 non-metric multidimensional scale (NMDS) could not distinguish microbiota community
48 structures between aerobic and anaerobic sample transport groups ($P = 0.864$); yet could
49 distinguish microbiota community structures between healthy and fat-metabolic disorder groups
50 ($P = 0.049$), along the Pearson's correlated clinical parameters (i.e. age, liver stiffness, GGT,
51 BMI, and TC), the significant associated bacterial species, and their microbial metabolic
52 functions. For examples, genera such as *Ruminococcus* and *Bifidobacterium* were exhibited in
53 healthy human gut and provided functions in metabolisms of cofactors and vitamins,
54 biosynthesis of secondary metabolites against gut bacterial pathogens, energy metabolisms,
55 digestive system, and carbohydrate metabolism; and these characteristics were also predicted as
56 healthy subject markers with the significant LEfSe scores. In conclusion, this study demonstrated
57 that short term aerobic sample collection and transport (< 48 hours) did not statistically affected
58 the microbiota and quantitative microbiota analyses in alpha and beta diversity measurements.
59 The study also demonstrated that the short term aerobic sample collection and transport still
60 allowed fecal microbiota differentiations between healthy and fat-metabolic disorder subjects,
61 similar with anaerobic sample collection and transport. Moreover, the microbiota related
62 metabolic function potentials and bacterial species biomarkers in healthy and fat-metabolic
63 disorder were suggested with statistic bioinformatics, albeit limitation of inter-individual human
64 differences such as sex and diet patterns.

65

66 **Keywords**

67 Human gut microbiome, Microbiota, 16S rRNA gene sequencing, Bacteria diversity, Aerobic
68 and anaerobic sample transport, Fecal, Fat-metabolic disease

69

70

71 **Introduction**

72 Human gastrointestinal microbiota is the most complex and dynamic microbial diversity
73 of estimated trillion bacterial cells, which include culture-independent and anaerobic bacteria.
74 These bacterial communities were also found diverse among different ethnics, ages, and health
75 status (*Reynoso-García et al., 2022; HMP Consortium, 2012a; HMP Consortium, 2012b*). The
76 gut bacterial diversity plays a crucial role in a health (symbiosis) status, for instances, supporting
77 proper fat metabolisms and gut leakage immune responses, antimicrobials, metabolites, and
78 nutrients e.g. vitamins B and K (*Reynoso-García et al., 2022; Valdes et al., 2018*). Perturbation
79 of the gut microbiota (dysbiosis) can cause risks to multiple diseases, such as fat metabolic
80 disorders, inflammatory bowel disease and other autoimmune diseases, lupus erythrematosous,
81 and cancer (*Hrncir, 2022*). Fat (or lipid) metabolism disorders are defined an improper process
82 human's body uses to make energy from food, and can cause a harmful amount of lipids
83 deposited in your body that may damage important tissues and organs, such as peripheral blood,
84 liver, and brain (*Handzlik et al., 2023; Yan et al., 2023*). Subsequently, the studies of gut
85 bacterial communities via fecal samples using 16S rRNA gene high-throughput sequencing have
86 become widely performed owing to its powerful identification in a culture-independent manner
87 (*Caporaso et al., 2011; Dailey et al., 2019; Kousgaard et al., 2020; Human Microbiome Project
88 Consortium, 2012a*), and our study thereby compared influences of aerobic and anaerobic sample
89 transport materials on gut (fecal) microbiota and also analyzed if the differences might affect
90 when interpretation in healthy and gut disease, in which the fat-metabolic disease presents as
91 example.

92

93 Many studies had investigated effects of sample collection preservatives and length of
94 sample storage to guideline fecal sample handling and storage for gut microbiome analyses. For
95 instances, -80°C was respected a standard choice for long-term (≥ 6 months) sample storage
96 temperature, and a common chemical such as 70% ethanol was reported sufficient for sample
97 preservative while other researches presented FTA cards and the OMNIgene Gut kit (*Hsu et al.*,
98 *2019*; *Ma et al.*, *2020*; *Song et al.*, *2016*; *Watson et al.*, *2019*). Fecal microbiota in these different
99 preservatives showed variable generally after 1 week of sample storage. For sample processing,
100 general protocols recommended cold sample transport ($\leq 4^{\circ}\text{C}$) within 24-48 h after sample
101 collection (*Gorzalak et al.*, *2015*; *Liang et al.*, *2020*; *Moossavi et al.*, *2019*; *Song et al.*, *2016*).
102 Subsequently, our study processed metagenomic extraction immediately after each sample
103 collection and cold transport (within 24 h) to prevent any bias. Our analysis of aerobic vs.
104 anaerobic sample transport materials present an interesting factor in local clinical sample
105 collection settings. In local clinical settings, an anaerobic sample transport material is sometimes
106 unaccessible and the samples are collected-transported aerobically in typical sterile
107 polypropylene containers in 24-48 h without DNA preservatives (*Dore et al.*, *2015*; *Wesolowska-*
108 *Andersen et al.*, *2014*). This aerobic condition may cause an oxygen toxicity to extremely
109 oxygen-sensitive bacteria, affecting fecal microbiota and quantitative microbiota analyses
110 (*Ndongo et al.*, *2020*; *Taur et al.*, *2018*). For examples, some bacteria such as *Faecalibacterium*
111 spp. are unable to retain cell viability for > 2 min of oxygen exposure (*Duncan et al.*, *2002*). To
112 date, a limited studies have investigated an impact of aerobic and anaerobic sample transport
113 materials without DNA preservative on quantitative microbiota whether this affects an ability to
114 differentiate between healthy and metabolic-disease gut microbial diversity (*Fofanov et al.*,

115 2018; Jenkins et al., 2018; Martínez et al., 2019). Our analyses included taxonomic composition,
116 alpha diversity, beta diversity, bacterial quantification, correlation with clinical factors for fat-
117 metabolic disorder, and the microbial community and species potential metabolic functions.

118

119 **Materials and Methods**

120 **Participant's recruitment, fecal sample collections and metagenomic extraction**

121 Nine healthy and eleven fat-metabolic disorder Thai participants, males and females of
122 age range 24-43 years, were recruited and all methods used in this study were in accordance with
123 the guidelines by the ethic approval. The ethical approval for the study was granted by
124 Institutional Review Board, Faculty of Medicine, Chulalongkorn University (no. 735/61).
125 Written informed consent was obtained from all participants in this study. Fecal samples were
126 collected in fecal containers with one aerobic and one anaerobic transport materials. For aerobic
127 transport material, the fecal container was sealed and placed in a plastic bag. For anaerobic
128 transport material, the fecal container was sealed and placed in the AnaeroPack-Anaero
129 (Mitsubishi Gas Chemical, Tokyo, Japan) (less than 0.1% O₂ and more than 15% CO₂) (*van*
130 *Horn et al., 1997; Wen et al., 2021*). The samples were transported on the same day of fecal
131 collection in cold temperature ($\leq 4^{\circ}\text{C}$) and processed immediately for metagenomic extraction
132 using DNeasy PowerSoil Pro Kit (Qiagen, Hilden, Germany) following manufacturer's
133 instruction (*Wongsaroj et al., 2021; Ondee et al., 2022*). The metagenomic DNA was qualified
134 and quantified by agarose gel electrophoresis and nanodrop spectrophotometry (A260 and
135 A260/A280, respectively). Schematic experimental design was illustrated in Fig. 1.

136

137 **16S rRNA gene V3-V5 library preparation and MiSeq sequencing**

138 PCR amplification of the 16S rRNA gene at the V3-V5 region was performed using the
139 universal prokaryotic primers 342F (5'-GGRGGCAGCAGTNGGGAA-3') and 895R (5'-
140 TGCGDCCGTACTCCCCA-3') with appended barcode and adaptor sequences (*Castelino et al.*,
141 *2017*; *Wongsaroj et al.*, *2021*; *Dityen et al.*, *2022*). Briefly, each PCR reaction comprised 1×
142 EmeraldAmp GT PCR Master Mix (TaKaRa, Shiga, Japan), 0.2 μM of each primer, and 50-100
143 ng of the genomic DNA in a total volume of 75 μL. The PCR conditions were 94°C 3 min, and
144 25 cycles of 94°C 45 s, 50°C 1 min and 72°C 1 min 30 s, followed by 72°C 10 min. A minimum
145 of two independent PCR reactions were performed and pooled to prevent PCR stochastic bias.
146 Then, the ~640-base pair (bp) amplicon was excised from agarose gel resolution and purified
147 using PureDireX PCR Clean-Up & Gel Extraction Kit (Bio-Helix, Keelung, Taiwan), and
148 quantified using a Qubit 3.0 Fluorometer and Qubit dsDNA HS Assay kit (Invitrogen, Waltham,
149 USA). Finally, 180 ng of each barcoded amplicon product was pooled for sequencing using the
150 Miseq600 platform (Illumina, San Diego, CA, USA), along with the sequencing primers and
151 index sequence (*Caporaso et al.*, *2012*; *Wongsaroj et al.*, *2021*; *Dityen et al.*, *2022*; *Ondee et al.*,
152 *2022*), at the Omics Sciences and Bioinformatics Center, Chulalongkorn University (Bangkok,
153 Thailand).

154

155 **Quantification of total bacteria copy number**

156 The 16S rRNA gene qPCR was performed to quantify total bacteria in copy unit, using
157 universal primers 1392F (5'-CGGTGAATACGTTTCYCGG-3') and 1492R (5'-
158 GGTTACCTTGTTAC GACTT-3'), and Quantinova SYBR green PCR Master Mix (Qiagen,
159 Hilden, Germany) in a 20 μL total volume and 1 ng metagenomic DNA (or reference DNA), as

160 previously established (Suzuki *et al.*, 2000; Oldham & Duncan 2012; Wongsaroj *et al.*, 2021).
161 The qPCR thermocycling conditions were 95°C 5 min, followed by 40 cycles of 95°C 5 s and
162 60°C 10 s, and ended with a 50-99°C melting curve analysis to validate a single proper amplicon
163 peak (i.e. neither primer-dimer nor non-specific amplification). The reference for copy number
164 computation was *Escherichia coli*, in which the ~120-bp 1392F-1492R amplicon fragments were
165 cloned into pGEM-T-Easy Vector (Promega, Wisconsin, USA) and the recombinant plasmids
166 were transformed into competent *E. coli* DH5 α for expression (Hanahan *et al.*, 1991). The
167 inserted fragments were verified by colony PCR using the primers M13F (on vector) and 1492R
168 (inserted fragment). Ten-fold serial dilutions of the extracted plasmids (10^5 - 10^{10} copies/ μ L) were
169 used as the reference standard curves in the bacterial copy number computation as following
170 equation (Smith *et al.*, 2006).

$$171 \quad \text{Copy number per } \mu\text{L} = \frac{\text{concentration (ng}/\mu\text{L}) \times 6.023 \times 10^{23} \text{ (copies/mol)}}{\text{length (bp)} \times 6.6 \times 10^{11} \text{ (ng/mol)}}$$

172 The qPCR experiments were performed using Rotor-GeneQ (Qiagen, Hilden, Germany).
173 Three replicates were conducted per reaction. The bacteria copy number of each sample was
174 quantified against the reference standard curve by Rotor-Gene Q Series Software (Qiagen).
175

176 **Bioinformatic and statistical analyses for bacterial microbiota diversity and potential** 177 **metabolisms**

178 Raw sequences (reads) were processed following Mothur 1.39.5's standard operation
179 procedures for MiSeq (Schloss *et al.*, 2009) (<https://github.com/mothur/mothur/releases/>),
180 including removal of (a) reads shorter than 100 nucleotides (nt) excluding primer and barcode
181 sequences, (b) ambiguous bases ≥ 4 , (c) chimera sequences, and (d) homopolymer of > 7

182 homopolymers. The quality sequences were aligned with the 16S rRNA gene SILVA 13.2
183 (*McDonald et al., 2012*) and Greengenes 13.8 (*Quast et al., 2013*) to remove lineages of
184 mitochondria, chloroplasts and eukaryotes, and were clustered into operational taxonomic units
185 (OTU) with 97% nt similarity (78% for phylum, 88% order, 91% class, 93% family, 95% genus,
186 and 97% species) based on naïve Bayesian taxonomic method with default parameters (*Wang et*
187 *al., 2007*). Samples were normalized for an equal sequencing depth (7,137 quality sequences per
188 sample), and the total bacteria copy number from the 16S rRNA gene qPCR data were analyzed
189 together with the percent microbiota composition to yield the quantitative microbiota
190 (*Vandeputte et al., 2017a; Vandeputte et al., 2017b; Jian et al., 2018; Wongsaroj et al., 2021*).
191 Alpha diversity including Good's coverage index (percent sequence coverage to true estimate),
192 rarefaction curve, Chao1 richness, inverse Simpson and Shannon diversity; and beta diversity
193 including Smith theta (Thetan), Sorenson (Sorabund), Morisita–Horn, Yue and Clayton theta
194 (Thetayc), Bray-Curtis (BC), Jaccard (jclass), and Lennon (Lennon) coefficients, and two-
195 dimension non-metric multidimensional scaling (NMDS), were computed using Mothur 1.39.5
196 (*Schloss et al., 2009; Schloss, 2020*). Estimate of the microbial metabolic profiles was
197 determined by PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of
198 Unobserved States) based on the reference genome annotations in KEGG (Kyoto Encyclopedia
199 of genes and genomes pathways) (*Langille et al., 2013*), and statistically compared by STAMP
200 (Statistical Analysis of Metagenomic Profiles) (*Parks et al., 2014*). The differences in microbial
201 metabolic profiles were further analyzed by linear discriminant analysis effect size (LEfSe)
202 method with pairwise Kruskal–Wallis and Wilcoxon tests to identify the microbial metabolic
203 biomarker representing healthy and disease groups. For general statistics, the non-parametric
204 multiple *t*-tests were used and a *P*-value < 0.05 was considered significant.

205

206 Availability of supporting data

207 Nucleic acid sequences in this study were deposited in an NCBI open access Sequence
208 Read Archive database, accession number PRJNA1020208.

209

210 Results**211 16S rRNA gene sequencing results and percent microbiota compositions**

212 The 16S rRNA gene sequencing yielded 2,365,959 total raw sequences (Table S1:
213 aerobic sample transport 1,517,643 sequences, and anaerobic sample transport 848,316
214 sequences), and 1,623,517 total quality sequences (aerobic sample transport 1,062,335
215 sequences, and anaerobic sample transport 561,182 sequences). The average quality sequences
216 per sample was $40,587 \pm 24,139$ (avg. \pm SD), and the numbers of OTUs ranged 5-10 at phylum
217 (Table 1: aerobic sample transport 6.80 ± 1.19), and anaerobic sample transport 848,316
218 sequences), 55-93 genus, and 77-133 species levels, respectively (Table S1 and Table 1). The
219 number of OTUs at phylum, genus and species levels were found approximately equal between
220 aerobic and anaerobic sample transports (Table 1: phylum OTUs 6.55 ± 1.19 aerobic, 7.05 ± 1.23
221 anaerobic; genus OTUs 71.40 ± 10.45 aerobic, 72.70 ± 11.29 anaerobic; and species OTUs
222 101.15 ± 16.83 aerobic, 101.60 ± 15.67 anaerobic). Following the successfully high number of
223 quality sequences, the Good's coverage (percent sequence coverage to true estimate) of all
224 samples were above 99.5% at phylum, genus and species level OTUs (Table S1), provided that
225 the Good's coverage index at phylum was averagely 100%, genus 99.82% and species 99.72%
226 (Table 1). Subsequently, once performed data normalization of all samples each to the same

227 sequencing depth received the relative plateau rarefaction curves with avg. > 99% Good's
228 coverages (Fig. S1), and confirmed our further microbiota bioinformatic analyses without bias
229 from various quality sequencing numbers per sample.

230

231 The distribution of percent bacterial compositions at phylum, genus, and species levels
232 across participants (adults) albeit healthy or fat-metabolic disorder disorders were compared
233 between aerobic vs. anaerobic sample transport material groups, and no statistical difference
234 between groups were found (AMOVA, $P > 0.05$) (Fig. 2). In brief, five core phyla ranging from
235 Firmicutes (averagely, $52.03 \pm 17.30\%$), Bacteroidetes ($24.32 \pm 14.11\%$), Proteobacteria,
236 Actinobacteria, to Fusobacteria, were dominated. The latter three phyla accounted averagely <
237 24% in total. Twenty-two bacterial genera and 24 bacterial species OTUs that exhibited more
238 than 1% relative abundances, each were compared between aerobic vs. anaerobic sample
239 transport material groups, and no statistical difference were found ($P > 0.05$) (Table S2). This
240 indicated no statistical difference in percent microbiota compositions at phylum, genus and
241 species levels, between aerobic and anaerobic sample transport groups.

242

243 **Quantitative microbiota composition analyses between aerobic and anaerobic sample** 244 **transport groups**

245 Following the quantification of bacteria by the universal 16S rRNA gene qPCR, the
246 quantity of bacterial counts and the quantitative microbiota compositions could be analyzed. The
247 quantity of bacterial counts were found no significantly different between aerobic and anaerobic
248 sample transport groups (Fig. 3A: $P = 0.057$). Noted that the relatively low in aerobic sample

249 transport group was due to ID3a and the relatively high in anaerobic sample transport group was
250 due to ID1an; if except these two, the average bacterial counts of both groups will even become
251 closer to each other and P value increases (Fig. S2).

252

253 Next, the prevalence of nine bacterial genera corresponding to obligate (or strictly)
254 anaerobic and facultative anaerobic bacteria were quantitatively compared, and no significant
255 difference in quantity between aerobic vs. anaerobic sample transport groups were pointed (Fig.
256 3B). The obligate anaerobic *Bacteroides* spp. were found most dominated than other obligate
257 anaerobic bacterial genera in both groups and presented in approximately comparable counts,
258 followed by *Prevotella*, *Faecalibacterium*, *Oscillospira*, *Bifidobacterium*, and the facultative
259 anaerobic *Haemophilus*, *Streptococcus* and *Enterococcus*, respectively. Nonetheless, the slight
260 but non-statistically significant higher counts of obligate anaerobic bacteria were showed, but
261 this trend was minute and found inconsistent for facultative anaerobic bacteria genera (Fig. 3B),
262 highlighting the differences in obligate vs. facultative oxygen requirement effect yet at the non-
263 significant statistic. Overall, the percent microbiota composition and the quantitative microbiota
264 did not demonstrate significant difference between aerobic and anaerobic sample transport
265 materials. Subsequently, the alpha diversity by OTU species richness (OTUs and Chao1) and
266 OTU species diversity (inverse Simpson and Shannon) showed very high P values between
267 0.3827 and 0.9497 (Fig. 4), and the beta diversity among individual samples belonging aerobic
268 and anaerobic sample transport groups showed no separate clustering pattern (Fig. 5A). Noted
269 that the detail analyses of alpha diversity at OTU phylum and genus levels were also analyzed
270 and no statistic differences were found ($P > 0.05$) (Fig. S3). Additionally, other beta diversity
271 coefficients, such as Sorabund, Morisita-Horn, Thetayc and Bray-Curtis, were computed and all

272 dissimilarity coefficient indices did not separate the microbiota community differences between
273 aerobic and anaerobic sample transport groups (Table S3: $P > 0.05$).

274

275 **Quantitative microbiota analyses between healthy and fat-metabolic disorder groups**

276 When we analyzed the quantitative microbiota structure differences based on beta
277 diversity coefficients and statistics between healthy vs. fat-metabolic disorder (from now on
278 referred as “unhealthy”) groups, both community structures demonstrated relatively separate
279 clusters with significant statistic (Fig. 5B: enclosed green circle for healthy subjects and red
280 circle for mostly unhealthy subjects, $P = 0.049$). Together, many clinical parameters
281 corresponding to fat-metabolic disorders demonstrated statistically ($P < 0.05$: age, liver stiffness,
282 GGT, BMI, and TC) and non-statistically (i.e., AST, ALT, TG, LDL, and CAP) associated the
283 same direction with the unhealthy microbiota community structure (Fig. 5C). Fig. 5D exhibited
284 bacterial species that significantly associated with healthy community structure pattern such as
285 *Prevotella*, *Haemophilus* and *Bacteroides plebeius*; and unhealthy community structure such as
286 *Clostridium*, *Ruminococcus* and *Bacteroides*.

287

288 **Metabolic function prediction levels via quantitative profiles of prevalent health-associated** 289 **bacteria, and microbial metabolic function species biomarkers for healthy and fat-** 290 **metabolic disorder groups**

291 Potentially important microbial related metabolic functions were analyzed via
292 quantitative profiles of reported and prevalent health-associated bacterial OTUs, including
293 *Bacteroides*, *Prevotella*, *Megamonas*, *Bifidobacterium*, *Hemophilus*, *Clostridium*, *Ruminococcus*

294 and Pasteurellaceae (Wu, Bushmanc & Lewis, 2013; Schirmer et al., 2019; Sun et al., 2020; Sabo
295 & Dumitrascu, 2021). The general most active microbial related functions were in metabolism
296 pathway (49.92%: primarily amino acid and carbohydrate metabolisms followed by energy,
297 cofactors and vitamins, lipid and xenobiotics biodegradation metabolisms), 19.94% in genetic
298 information processing, 16.22% environmental information processing, 3.11% cellular process,
299 0.91% human diseases, 0.65% organismal systems, and 5.09% poorly characterized. The OTUs
300 representing *Bacteroides* and *Prevotella copri* represented the general topmost bacterial
301 metabolisms (Fig. 6A). Nonetheless, the relative abundances of these two species and other
302 prevalent health-associated bacteria showed the dynamic functions in categories of metabolisms,
303 cellular process, and genetic information processing between healthy and fat-metabolic disorder
304 groups, in orderly. For instances, the relatively more abundances of amino acid, carbohydrate
305 and energy metabolism functions, cellular process, genetic information processing and human
306 diseases were reported in the fat-metabolic disorder group. *Prevotella copri*, *Prevotella stercorea*
307 and *Bacteroides plebeius* were estimated more diverse and abundant functions in the fat-
308 metabolic disorder group while *Bacteroides* and *Bifidobacterium longum* were estimated the
309 more diverse and abundant in healthy group (Fig. S4). These microbial metabolism differences
310 between groups allowed LEfSe to identify the specific microbial metabolic functions along the
311 bacterial species as the biomarkers to differentiate between healthy vs. fat-metabolic disorder
312 groups, with statistic *P* values. *Prevotella copri* and *Bacteroides plebeius* were the biomarkers
313 for the fat-metabolic disorder and their microbial metabolic functions included many functions
314 involved in diseases (immune system diseases, metabolic diseases, and neurodegenerative
315 diseases). On the other hand, more numbers of bacterial species and their microbial metabolic
316 functions were the biomarkers for the healthy group, supporting the diverse microbial related

317 metabolic functions in healthy human guts; and noted that the commonly reported functions were
318 in metabolism and organismal systems pathways meanwhile the human disease pathway was rare
319 for the healthy group (Fig. 6B).

320

321 **Discussion**

322 As intestine occupies the most number and diversity of bacteria in human body, fecal
323 microbiome has shown the important field to study many bacterial interactions with human
324 healthy (or diseases), and the fat-metabolic disorder represent one common related disorder with
325 fecal microbiota dysbiosis. Due to variation in sample transport materials, especially in local and
326 limited research resource settings, the anaerobic sample transport materials might be utilized.
327 Hence, this study analyzed influences of aerobic and anaerobic sample transport materials on
328 percent composition and quantitative composition of gut (fecal) microbiota, and also identified
329 whether these influences could affect the interpretation in microbiomes of healthy compared with
330 the fat-metabolic disorder. Further, we could describe the percent and quantitative microbiota
331 differences in healthy and fat-metabolic disorder subjects disrespect of aerobic or anaerobic
332 sample transport materials.

333

334 Our study successfully obtained microbiota results in percent and quantitative
335 compositions. The number of quality sequences in each sample allowed reliable Good's
336 coverage index score for OTU diversity and rarefaction curve. Comparing between aerobic and
337 anaerobic sample transport materials, the core bacterial compositions, in both percentages and
338 quantitative counts, showed no statistical difference. This supported the no statistic difference in
339 alpha diversity that included numbers of OTUs, Chao1 richness, inverse Simpson, and Shannon

340 diversity indices. Further, analyses of obligate anaerobic and facultative anaerobic bacteria were
341 compared and still no statistical difference in these bacterial species between the aerobic and
342 anaerobic sample transport groups. Supportively, the beta diversity analysis by NMDS could not
343 separate bacterial communities of aerobic from anaerobic sample transport groups ($P = 0.864$).
344 Overall, our study indicated no influence between aerobic and anaerobic sample transport
345 materials during sample collection and sample transport (provided that the metagenomic
346 extraction was performed within 2 days) on fecal microbiota and fecal quantitative microbiota.
347 Our results were in consistent with Taguer et al. (2021) that short period of oxygen exposure did
348 not affect the nucleic acid content and changes of bacterial microbiota. Moreover, studies
349 reported that the fecal samples for microbiome studies might be kept without any DNA stabilizer
350 reagent at 4°C for up to 8 weeks and at -20°C for the longer period (Choo et al., 2015; Song et
351 al., 2016). Moreover, some obligate anaerobes could partially reduce pressure of aerobic
352 (oxygen) environment by consuming oxygen via their bacterial oxidase enzymes (Baughn &
353 Malamy, 2004): for examples, a conserved cytochrome *bd* family enzymes in many bacterial
354 species in phyla Firmicutes, Bacteroidetes, Actinomycetes and Proteobacteria, allowing the
355 bacterial tolerance in the presence of oxygen for several hours (Borisov et al., 2021). Yet, when
356 possible, the minimizing oxygen exposure remains the gold standard fecal collection and
357 transport (Burz et al., 2019).

358

359 Next, we analyzed if these microbiota communities remained associated and able to be
360 distinguished by a fat-metabolic disorder, an example of well-known disease that could be
361 affected by the gut microbiota dysbiosis (Rothschild et al., 2018; HMP Consortium, 2012b;
362 Zheng et al., 2020). The beta diversity analyses by NMDS could distinguish the different

363 microbiota community structures between healthy and this disease state, and many clinical
364 factors representing the fat-metabolic disorders (*Dominianni et al., 2015; Loo et al., 2017; Liu et*
365 *al., 2019a; Xu et al., 2019; Zheng et al., 2020*) were statistically correlated with the fat-metabolic
366 disorder microbiota subjects (from both aerobic and anaerobic sample transport groups) (e.g.
367 age, liver stiffness, GGT, BMI, and TC). In addition, we could identify the bacterial OTUs that
368 statistically associated with the healthy vs. fat-metabolic disorder, their microbial metabolic
369 functions, and the potential biomarkers for bacterial species and correlated metabolisms in
370 healthy vs. fat-metabolic disorder. For instances, genera such as *Ruminococcus* and
371 *Bifidobacterium* were also reported previously in healthy human gut and provided functions in
372 short chain fatty acid producers, metabolisms of cofactors and vitamins, biosynthesis of
373 secondary metabolites against gut bacterial pathogens, energy metabolisms, digestive system,
374 and carbohydrate metabolism (*Ze et al., 2012; Christopherson et al., 2014; Matijašić et al.,*
375 *2014;*). Noted that the presence of *H. parainfluenzae* was reported no any negative effect in gut
376 health (*Kosikowska et al., 2016; Tanner et al., 2016*). Additionally, the microbial functions
377 involved human disease was rare found in the healthy than the fat-metabolic disorder groups
378 (Fig. 6B).

379

380 For fat-metabolic disorder group, *Prevotella copri* and *Bacteroides plebeius* had been
381 reported as potential gut pathogens for cardiac valve calcification and cardiovascular disease (*Liu*
382 *et al., 2019b*). However, the prevalence of genus *Prevotella* could be found in healthy gut, and
383 this genus was reported linked with high-fiber diet consumption (*Arumugam et al., 2011*).
384 Hence, the reason that we observed this genus correlated with the fat-metabolic disorder could be
385 biased by the subjects' diets, which we did not have information in study. Furthermore,

386 limitation in this study included a small number of samples, which could hinder the correlation
387 and bacterial species identification of the microbiota and quantitative microbiota with the fat-
388 metabolic disorder.

389

390 **Conclusions**

391 The study first analyzed fecal bacterial microbiota and quantitative microbiota, and
392 revealed no influence of anaerobic sample transport material on the microbiota and quantitative
393 microbiota. This supported studies that short term aerobic sample collection and transport does
394 not statistically affected the microbiota analyses, with $\leq 4^{\circ}\text{C}$ sample storage and sample
395 processing within 48 h are required. Our study could also able to demonstrate the gut microbiota
396 differences between healthy and fat-metabolic disorder in both aerobic and anaerobic sample
397 transport collections, and analyze quantitative microbiota related microbial metabolic potentials
398 and bacterial species biomarkers in Thai adult subjects. This disease gut microbiota dysbiosis
399 factor exhibited albeit inter-individual human differences like sex and diet patterns.

400

401 **Acknowledgments**

402 The study was supported by Thailand Science Research and Innovation Fund
403 Chulalongkorn University (CU_FRB65_he(68)_131_23_61), Thailand Science Research and
404 Innovation (RDG6150124), and the 90th Anniversary of Chulalongkorn University Scholarship.
405 The funders had no role in study design, data collection and analysis. The authors also
406 acknowledged Matanee Palasuk, Piraya Chathanathon, Paweena Ouying and Chitrasak
407 Kullapanich for their technical assistances or advice.

408

409 **Authors' Contributions**

410 NT performed molecular biology experiments and data analysis, and drafted the
411 manuscript. LW helped molecular biology experiments and data analysis. KJ helped clinical
412 sample collections. KP provided samples. KP and NS advised and conceived the study. NS
413 designed the study, coordinated the experiments and data analysis, and wrote the manuscript. All
414 authors read and approved the final manuscript

415

416 **Conflict of Interest**

417 The authors declare no conflict of interest.

418

419

420 **References**

421 Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J,
422 Bruls T, Batto J-M, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen
423 T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F,
424 Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims
425 S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM,
426 Brunak S, Doré J, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara
427 C, Chervaux C, Cultrone A, Delorme C, Denariáz G, Dervyn R, Foerstner KU, Friss C,
428 van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste
429 C, Kaci G, Knol J, Kristiansen K, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux
430 A, Melo Minardi R, M'Rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M,

- 431 Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E,
432 Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P, and Meta HITC. 2011.
433 Enterotypes of the human gut microbiome. *Nature* 473:174-180. doi:
434 10.1038/nature09944
- 435 Baughn AD, Malmay MH. 2004. The strict anaerobe *Bacteroides fragilis* grows in and benefits
436 from nanomolar concentrations of oxygen. *Nature* 427:441-444. doi:
437 10.1038/nature02285
- 438 Borisov VB, Siletsky SA, Paiardini A, Hoogewijs D, Forte E, Giuffrè A, Poole RK. 2021.
439 Bacterial Oxidases of the Cytochrome bd Family: Redox Enzymes of Unique Structure,
440 Function, and Utility As Drug Targets. *Antioxidants & Redox Signaling* 34:1280-1318.
441 doi: 10.1089/ars.2020.8039
- 442 Burz SD, Abraham A-L, Fonseca F, David O, Chapron A, Béguet-Crespel F, Cénard S, Le Roux
443 K, Patrascu O, Levenez F, Schwintner C, Blottière HM, Béra-Maillet C, Lepage P, Doré
444 J, Juste C. 2019. A Guide for Ex Vivo Handling and Storage of Stool Samples Intended
445 for Fecal Microbiota Transplantation. *Scientific Reports* 9:8897. doi: 10.1038/s41598-
446 019-45173-4
- 447 Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, Knights D,
448 Gajer P, Ravel J, Fierer N, Gordon JI, Knight R. 2011. Moving pictures of the human
449 microbiome. *Genome Biology* 12:R50. doi: 10.1186/gb-2011-12-5-r50
- 450 Caporaso, JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM, Betley
451 J, Fraser L, Bauer M, Gormley N, Gilbert JA, Smith G, Knight R. 2012. Ultra-high-

- 452 throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms.
453 *ISME J* 6:1621–1624. doi: 10.1038/ismej.2012.8
- 454 Castelino M, Eyre S, Moat J, Fox G, Martin P, Ho P, Upton M, Barton A. 2017. Optimisation of
455 methods for bacterial skin microbiome investigation: primer selection and comparison of
456 the 454 versus MiSeq platform. *BMC Microbiology* 17:23. doi: 10.1186/s12866-017-
457 0927-4
- 458 Choo JM, Leong LEX, Rogers GB. 2015. Sample storage conditions significantly influence
459 faecal microbiome profiles. *Scientific Reports* 5:16350. doi: 10.1038/srep16350
- 460 Christopherson MR, Dawson JA, Stevenson DM, Cunningham AC, Bramhacharya S, Weimer
461 PJ, Kendzioriski C, Suen G. 2014. Unique aspects of fiber degradation by the ruminal
462 ethanologen *Ruminococcus albus* 7 revealed by physiological and transcriptomic
463 analysis. *BMC Genomics* 15:1066. doi: 10.1186/1471-2164-15-1066
- 464 Dailey FE, Turse EP, Daglilar E, Tahan V. 2019. The dirty aspects of fecal microbiota
465 transplantation: a review of its adverse effects and complications. *Current Opinion in*
466 *Pharmacology* 49:29-33. doi: 10.1016/j.coph.2019.04.008
- 467 Dityen K, Soonthornchai W, Kueanjinda P, Kullapanich C, Tunsakul N, Somboonna N,
468 Wongpiyabovorn J. 2022. Analysis of cutaneous bacterial microbiota of Thai patients
469 with seborrheic dermatitis. *Experimental Dermatology* 31:1949-1955. doi:
470 10.1111/exd.14674
- 471 Dominianni C, Sinha R, Goedert JJ, Pei Z, Yang L, Hayes RB, Ahn J. 2015. Sex, body mass
472 index, and dietary fiber intake influence the human gut microbiome. *PLoS One*
473 10:e0124599. doi: 10.1371/journal.pone.0124599

- 474 Dore J, Ehrlich SD, Levenez F, Pelletier E, Alberti A, Bertrand L, Bork P, Costea PI, Sunagawa
475 S, Guarner F, Manichanh C, Santiago A, Zhao L, Shen J, Zhang C, Versalovic J, Luna
476 RA, Petrosino J, Yang H, Li S, Wang J, Allen-Vercoe E, Gloor G, Singh B, International
477 Human Microbiome Standards (IHMS) Consortium. 4 December 2015. IHMS_SOP 02
478 V1: Standard operating procedure for fecal samples self-collection, laboratory analysis
479 handled within 4 hours ($x \leq 4$ hours). International Human Microbiome Standards. pages
480 1-13.
- 481 Duncan SH, Hold GL, Harmsen HJM, Stewart CS, Flint HJ. 2002. Growth requirements and
482 fermentation products of *Fusobacterium prausnitzii*, and a proposal to reclassify it as
483 *Faecalibacterium prausnitzii* gen. nov., comb. nov. *Int J Syst Evol Microbiol* 52:2141-
484 2146. doi: 10.1099/00207713-52-6-2141
- 485 Fofanov VY, Furstenau TN, Sanchez D, Hepp CM, Cocking J, Sobek C, Pagel N, Walker F,
486 Chambers CL. 2018. Guano exposed: Impact of aerobic conditions on bat fecal
487 microbiota. *Ecol Evol* 8:5563-5574. doi: 10.1002/ece3.4084
- 488 Gorzelak MA, Gill SK, Tasnim N, Ahmadi-Vand Z, Jay M, Gibson DL. 2015. Methods for
489 Improving Human Gut Microbiome Data by Reducing Variability through Sample
490 Processing and Storage of Stool. *PLoS One* 10:e0134802. doi:
491 10.1371/journal.pone.0134802
- 492 Hanahan D, Jessee J, Bloom FR. 1991. Plasmid transformation of *Escherichia coli* and other
493 bacteria. *Methods Enzymology* 204:63-113. doi: 10.1016/0076-6879(91)04006-a
- 494 Handzlik MK, Gengatharan JM, Frizzi KE, McGregor GH, Martino C, Rahman G, Gonzalez A,
495 Moreno AM, Green CR, Guernsey LS, Lin T, Tseng P, Ideguchi Y, Fallon RJ, Chaix A,

- 496 Panda S, Mali P, Wallace M, Knight R, Gantner ML, Calcutt NA, Metallo CM. 2023.
497 Insulin-regulated serine and lipid metabolism drive peripheral neuropathy. *Nature*
498 614:118-124. doi: 10.1038/s41586-022-05637-6
- 499 Hrnčir T. 2022. Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic
500 Options. *Microorganisms* 10. doi: 10.3390/microorganisms10030578
- 501 Hsu YL, Chen CC, Lin YT, Wu WK, Chang LC, Lai CH, Wu MS, Kuo CH. 2019. Evaluation
502 and Optimization of Sample Handling Methods for Quantification of Short-Chain Fatty
503 Acids in Human Fecal Samples by GC-MS. *Journal of Proteome Research* 18:1948-
504 1957. doi: 10.1021/acs.jproteome.8b00536
- 505 Human Microbiome Project (HMP) Consortium. 2012a. A framework for human microbiome
506 research. *Nature* 486:215-221. doi: 10.1038/nature11209
- 507 Human Microbiome Project (HMP) Consortium. 2012b. Structure, function and diversity of the
508 healthy human microbiome. *Nature* 486:207-214. doi: 10.1038/nature11234
- 509 Jian C, Luukkonen P, Yki-Järvinen H, Salonen A, Korpela K. 2020. Quantitative PCR provides a
510 simple and accessible method for quantitative microbiome profiling. *PLoS ONE*
511 15:e0227285. doi: 10.1371/journal.pone.0227285
- 512 Jenkins SV, Vang KB, Gies A, Griffin RJ, Jun S-R, Nookaew I, Dings RPM. 2018. Sample
513 storage conditions induce post-collection biases in microbiome profiles. *BMC*
514 *Microbiology* 18:227. doi: 10.1186/s12866-018-1359-5
- 515 Kosikowska U, Rybojad P, Stępień-Pyśniak D, Żbikowska A, Malm A. 2016. Changes in the
516 prevalence and biofilm formation of *Haemophilus influenzae* and *Haemophilus*

- 517 *parainfluenzae* from the respiratory microbiota of patients with sarcoidosis. *BMC*
518 *Infectious Diseases* 16:449. doi: 10.1186/s12879-016-1793-7
- 519 Kousgaard SJ, Michaelsen TY, Nielsen HL, Kirk KF, Brandt J, Albertsen M, Thorlacius-Ussing
520 O. 2020. Clinical results and microbiota changes after faecal microbiota transplantation
521 for chronic pouchitis: a pilot study. *Scandinavian Journal of Gastroenterology* 55:421-
522 429. doi: 10.1080/00365521.2020.1748221
- 523 Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC,
524 Burkepille DE, Vega Thurber RL, Knight R, Beiko RG, Huttenhower C. 2013. Predictive
525 functional profiling of microbial communities using 16S rRNA marker gene sequences.
526 *Nature Biotechnology* 31:814-821. doi: 10.1038/nbt.2676
- 527 Liang Y, Dong T, Chen M, He L, Wang T, Liu X, Chang H, Mao J-H, Hang B, Snijders AM,
528 Xia Y. 2020. Systematic Analysis of Impact of Sampling Regions and Storage Methods
529 on Fecal Gut Microbiome and Metabolome Profiles. *mSphere* 5:10.1128/msphere.00763-
530 00719. doi: 10.1128/msphere.00763-19
- 531 Liu Y, Ding W, Wang HL, Dai LL, Zong WH, Wang YZ, Bi J, Han W, Dong GJ. 2019a. Gut
532 microbiota and obesity-associated osteoarthritis. *Osteoarthritis and Cartilage* 27:1257-
533 1265. doi: 10.1016/j.joca.2019.05.009
- 534 Liu Z, Li J, Liu H, Tang Y, Zhan Q, Lai W, Ao L, Meng X, Ren H, Xu D, Zeng Q. 2019b. The
535 intestinal microbiota associated with cardiac valve calcification differs from that of
536 coronary artery disease. *Atherosclerosis* 284:121-128. doi:
537 10.1016/j.atherosclerosis.2018.11.038

- 538 Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, Nakajima-Takagi Y, Iwama
539 A, Koga T, Sugimoto Y, Ozawa T, Nakamura M, Kumagai M, Watashi K, Taketo MM,
540 Aoki T, Narumiya S, Oshima M, Arita M, Hara E, Ohtani N. 2017. Gut Microbiota
541 Promotes Obesity-Associated Liver Cancer through PGE(2)-Mediated Suppression of
542 Antitumor Immunity. *Cancer Discovery* 7:522-538. doi: 10.1158/2159-8290.Cd-16-0932
- 543 Ma J, Sheng L, Hong Y, Xi C, Gu Y, Zheng N, Li M, Chen L, Wu G, Li Y, Yan J, Han R, Li B,
544 Qiu H, Zhong J, Jia W, Li H. 2020. Variations of Gut Microbiome Profile Under
545 Different Storage Conditions and Preservation Periods: A Multi-Dimensional Evaluation.
546 *Frontiers in Microbiology* 11:972. doi: 10.3389/fmicb.2020.00972
- 547 Martínez N, Hidalgo-Cantabrana C, Delgado S, Margolles A, Sánchez B. 2019. Filling the gap
548 between collection, transport and storage of the human gut microbiota. *Scientific Reports*
549 9:8327. doi: 10.1038/s41598-019-44888-8
- 550 Matijašić BB, Obermajer T, Lipoglavšek L, Grabnar I, Avguštin G, Rogelj I. 2014. Association
551 of dietary type with fecal microbiota in vegetarians and omnivores in Slovenia. *European*
552 *Journal of Nutrition* 53:1051-1064. doi: 10.1007/s00394-013-0607-6
- 553 McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, Andersen GL,
554 Knight R, Hugenholtz P. 2012. An improved Greengenes taxonomy with explicit ranks
555 for ecological and evolutionary analyses of bacteria and archaea. *Isme J* 6:610-618. doi:
556 10.1038/ismej.2011.139
- 557 Moossavi S, Engen PA, Ghanbari R, Green SJ, Naqib A, Bishehsari F, Merat S, Poustchi H,
558 Keshavarzian A, Malekzadeh R. 2019. Assessment of the impact of different fecal

- 559 storage protocols on the microbiota diversity and composition: a pilot study. *BMC*
560 *Microbiology* 19:145. doi: 10.1186/s12866-019-1519-2
- 561 Ndongo S, Khelaifia S, Lagier J-C, Raoult D. 2020. From anaerobes to aerointolerant
562 prokaryotes. *Human Microbiome Journal* 15:100068. doi: 10.1016/j.humic.2019.100068
- 563 Oldham AL, Duncan KE. 2012. Similar gene estimates from circular and linear standards in
564 quantitative PCR analyses using the prokaryotic 16S rRNA gene as a model. *PLoS ONE*
565 7:e51931. doi: 10.1371/journal.pone.0051931
- 566 Ondee T, Pongpirul K, Jancot K, Kanacharoen S, Lertmongkolaksorn T, Wongsaroj L,
567 Somboonna N, Ngamwongsatit N, Leelahavanichkul A. 2022. Lactiplantibacillus
568 plantarum dfa1 outperforms Enterococcus faecium dfa1 on anti-obesity in high fat-
569 induced obesity mice possibly through the differences in gut dysbiosis attenuation,
570 despite the similar anti-inflammatory properties. *Nutrients* 14:80. doi:
571 10.3390/nu14010080
- 572 Parks DH, Tyson GW, Hugenholtz P, Beiko RG. 2014. STAMP: statistical analysis of taxonomic
573 and functional profiles. *Bioinformatics* 30:3123-3124. doi:
574 10.1093/bioinformatics/btu494
- 575 Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. 2013. The
576 SILVA ribosomal RNA gene database project: improved data processing and web-based
577 tools. *Nucleic Acids Research* 41:D590-596. doi: 10.1093/nar/gks1219
- 578 Reynoso-García J, Miranda-Santiago AE, Meléndez-Vázquez NM, Acosta-Pagán K, Sánchez-
579 Rosado M, Díaz-Rivera J, Rosado-Quiñones AM, Acevedo-Márquez L, Cruz-Roldán L,
580 Tosado-Rodríguez EL, Figueroa-Gispert MDM, Godoy-Vitorino F. 2022. A complete

- 581 guide to human microbiomes: body niches, transmission, development, dysbiosis, and
582 restoration. *Frontiers in Systems Biology* 2:2022. doi: 10.3389/fsysb.2022.951403
- 583 Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva
584 A, Kalka IN, Bar N, Shilo S, Lador D, Vila AV, Zmora N, Pevsner-Fischer M, Israeli D,
585 Kosower N, Malka G, Wolf BC, Avnit-Sagi T, Lotan-Pompan M, Weinberger A, Halpern
586 Z, Carmi S, Fu J, Wijmenga C, Zhernakova A, Elinav E, Segal E. 2018. Environment
587 dominates over host genetics in shaping human gut microbiota. *Nature* 555:210-215. doi:
588 10.1038/nature25973
- 589 Sabo CM, Dumitrascu DL. 2021. Microbiota and the irritable bowel syndrome. *Minerva*
590 *Gastroenterol* 67:377-384. doi: 10.23736/S2724-5985.21.02923-5
- 591 Schirmer M, Garner A, Vlamakis H, Xavier RJ. 2019. Microbial genes and pathways in
592 inflammatory bowel disease. *Nature Review Microbiology* 17:497-511. doi:
593 10.1038/s41579-019-0213-6
- 594 Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA,
595 Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Horn DJV, Weber
596 CF. 2009. Introducing mothur: Open-Source, Platform-Independent, Community-
597 Supported Software for Describing and Comparing Microbial Communities. *Applied and*
598 *Environmental Microbiology* 75:7537-7541. doi: 10.1128/AEM.01541-09
- 599 Schloss, PD. 2020. Reintroducing mothur: 10 years later. *Appl Environ Microbiol* 86:e02343-19.
600 doi: 10.1128/AEM.02343-19.
- 601 Smith CJ, Nedwell DB, Dong LF, Osborn AM. 2006. Evaluation of quantitative polymerase
602 chain reaction-based approaches for determining gene copy and gene transcript numbers

- 603 in environmental samples. *Environmental Microbiology* 8:804-815. 10.1111/j.1462-
604 2920.2005.00963.x
- 605 Song SJ, Amir A, Metcalf JL, Amato KR, Xu ZZ, Humphrey G, Knight R. 2016. Preservation
606 methods differ in fecal microbiome stability, affecting suitability for field studies.
607 *mSystems* 1:e00021-16. doi: 10.1128/msystems.00021-16
- 608 Sun Q, Zhu L, Li Y, Cui Y, Jiang S, Tao N, Chen H, Zhao Z, Xu J, Dong C. 2020. A novel
609 inulin-type fructan from *Asparagus cochinchinensis* and its beneficial impact on human
610 intestinal microbiota. *Carbohydrate Polymers* 247:116761. doi:
611 10.1016/j.carbpol.2020.116761
- 612 Suzuki MT, Taylor LT, DeLong EF. 2000. Quantitative analysis of small-subunit rRNA genes in
613 mixed microbial populations via 5'-nuclease assays. *Applied Environmental*
614 *Microbiology* 66:4605–4614. doi: 10.1128/aem.66.11.4605-4614.2000
- 615 Taguer M, Quillier O, Maurice CF. 2021. Effects of oxygen exposure on relative nucleic acid
616 content and membrane integrity in the human gut microbiota. *PeerJ* 9:e10602. doi:
617 10.7717/peerj.10602
- 618 Tanner SA, Chassard C, Rigozzi E, Lacroix C, Stevens MJA. 2016. Bifidobacterium
619 thermophilum RBL67 impacts on growth and virulence gene expression of Salmonella
620 enterica subsp. enterica serovar Typhimurium. *BMC Microbiology* 16:46. doi:
621 10.1186/s12866-016-0659-x
- 622 Taur Y, Coyte K, Schluter J, Robilotti E, Figueroa C, Gjonbalaj M, Littmann ER, Ling L, Miller
623 L, Gyaltshen Y, Fontana E, Morjaria S, Gyurkocza B, Perales MA, Castro-Malaspina H,
624 Tamari R, Ponce D, Koehne G, Barker J, Jakubowski A, Papadopoulos E, Dahi P, Sauter

- 625 C, Shaffer B, Young JW, Peled J, Meagher RC, Jenq RR, van den Brink MRM, Giralto
626 SA, Pamer EG, Xavier JB. 2018. Reconstitution of the gut microbiota of antibiotic-
627 treated patients by autologous fecal microbiota transplant. *Sci Transl Med* 10. doi:
628 10.1126/scitranslmed.aap9489
- 629 Valdes AM, Walter J, Segal E, Spector TD. 2018. Role of the gut microbiota in nutrition and
630 health. *BMJ* 361:k2179. doi: 10.1136/bmj.k2179
- 631 van Horn KG, Warren K, Baccaglini EJ. 1997. Evaluation of the AnaeroPack system for growth
632 of anaerobic bacteria. *Journal of Clinical Microbiology* 35:2170-2173. doi:
633 10.1128/jcm.35.8.2170-2173.1997
- 634 Vandeputte D, Kathagen G, D'hoel K, Vieira-Silva S, Valles-Colomer M, Sabino J, Wang J, Tito
635 RY, Falony G, Raes J. 2017b. Quantitative microbiome profiling links gut community
636 variation to microbial load. *Nature* 551:507-511. doi: 10.1038/nature24460
- 637 Vandeputte D, Tito RY, Vanleeuwen R, Falony G, Raes J. 2017. Practical considerations for
638 large-scale gut microbiome studies. *FEMS Microbiology Review* 41:S154-s167. doi:
639 10.1093/femsre/fux027
- 640 Wang Q, Garrity GM, Tiedje JM, Cole JR. 2007. Naive Bayesian classifier for rapid assignment
641 of rRNA sequences into the new bacterial taxonomy. *Applied Environmental*
642 *Microbiology* 73:5261-5267. doi: 10.1128/aem.00062-07
- 643 Watson EJ, Giles J, Scherer BL, Blatchford P. 2019. Human faecal collection methods
644 demonstrate a bias in microbiome composition by cell wall structure. *Scientific Reports*
645 9:16831. doi: 10.1038/s41598-019-53183-5

- 646 Wen J, Wang D, Cheng L, Wu D, Qiu L, Li M, Xie Y, Wu S, Jiang Y, Bai H, Xu B, Lv H. 2021.
647 The optimization conditions of establishing an H9c2 cardiomyocyte
648 hypoxia/reoxygenation injury model based on an AnaeroPack System. *Cell Biology
649 International* 45:757-765. doi: 10.1002/cbin.11513
- 650 Wongsaroj L, Chanabun R, Tunsakul N, Prombutara P, Panha S, Somboonna N. 2021. First
651 reported quantitative microbiota in different livestock manures used as organic fertilizers
652 in the Northeast of Thailand. *Scientific Reports* 11:102. doi: 10.1038/s41598-020-80543-
653 3
- 654 Wesolowska-Andersen A, Bahl MI, Carvalho V, Kristiansen K, Sicheritz-Pontén T, Gupta R,
655 Licht TR. 2014. Choice of bacterial DNA extraction method from fecal material
656 influences community structure as evaluated by metagenomic analysis. *Microbiome* 2:19.
657 doi: 10.1186/2049-2618-2-19
- 658 Wu GD, Bushmanc FD, Lewis JD. 2013. Diet, the human gut microbiota, and IBD. *Anaerobe*
659 24:117-120. doi: 10.1016/j.anaerobe.2013.03.011
- 660 Xu C, Zhu H, and Qiu P. 2019. Aging progression of human gut microbiota. *BMC Microbiology*
661 19:236. doi: 10.1186/s12866-019-1616-2
- 662 Yan B, Sun Y, Fu K, Zhang Y, Lei L, Men J, Guo Y, Wu S, Han J, Zhou B. 2023. Effects of
663 glyphosate exposure on gut-liver axis: metabolomic and mechanistic analysis in grass
664 carp (*Ctenopharyngodon idellus*). *Science of the Total Environment* 902:166062. doi:
665 10.1016/j.scitotenv.2023.166062

666 Ze X, Duncan SH, Louis P, Flint HJ. 2012. *Ruminococcus bromii* is a keystone species for the
667 degradation of resistant starch in the human colon. *ISME Journal* 6:1535-1543. doi:
668 10.1038/ismej.2012.4

669 Zheng D, Liwinski T, Elinav E. 2020. Interaction between microbiota and immunity in health
670 and disease. *Cell Research* 30:492-506. doi: 10.1038/s41422-020-0332-7

671

672

673 **Figure Legends**

674 **Fig. 1.** Schematic diagram of experimental design.

675

676 **Fig. 2.** Relative percent gut microbiota compositions of aerobic and anaerobic transport groups at
677 phylum, genus and species levels.

678 Color shades represent bacterial phyla: yellow (Firmicutes), blue (Bacteroidetes), red

679 (Proteobacteria), grey (Fusobacteria), purple (Actinobacteria), white (Other), and pink

680 (unclassified bacterial phyla). The OTUs where Mothur could not identify the genus (or species)

681 names were denoted by small letters (o_ abbreviates order; f_, family; g_, genus and s_, species)

682 to the deepest taxonomic names that could be identified; k_ abbreviated kingdom bacteria but

683 unclassified phylum; and “Other” represented < 1% phylum (or genus, or species) OTUs.

684

685 **Fig. 3.** Quantification of bacterial counts for (A) average total bacterial counts and (B) average

686 strictly anaerobic and facultative anaerobic bacterial genera, comparing between aerobic and

687 anaerobic sample transport groups.

688 Data were presented as average \pm SD. Statistical differences between groups were tested using
689 Student's *t*-test ($P < 0.05$), and no statistical difference was found.

690

691 **Fig. 4.** Scatter plots showing individual and mean range alpha diversity data at species OTUs of
692 aerobic (filled circle) and anaerobic (empty square) sample transport groups, measured by (A)
693 number of OTUs, (B) Chao1 richness, (C) inverse Simpson diversity, and (D) Shannon evenness.
694 Statistical differences between groups were tested using Student's *t*-test ($P < 0.05$), and no
695 statistical difference was found: $P > 0.05$.

696

697 **Fig. 5.** Non-metric multidimensional scaling (NMDS) constructed from Thetan coefficients
698 displaying beta diversity among quantitative microbiota communities in aspects of (A) aerobic
699 and anaerobic sample transport groups and (B-D) health and fat-metabolic disorder (denoted
700 “unhealthy”) groups.

701 In (A) and (B), AMOVA test was performed to determine statistical separation between
702 designated groups ($P < 0.05$). In (C) and (D) showed the Pearson's correlations with health status
703 parameters and the representing bacterial species OTUs, respectively. A vector direction and
704 length represented the direction and strength of that parameter or OTU to the communities. A red
705 arrow indicated a statistically significant correlation parameter ($P < 0.05$), and a black arrow
706 indicated non-statistically significant correlation parameter ($P > 0.05$). In (C), GGT abbreviates
707 gamma-glutamyl transferase; BMI, body mass index; stiffness, liver stiffness indicates the non-
708 elasticity of the liver associated fat accumulation; TC, total cholesterol; AST, aspartate
709 aminotransferase; ALT, alanine aminotransferase; TG, triglyceride; LDL, low-density
710 lipoproteins; CAP, controlled attenuation parameter; and HDL, high-density lipoproteins.

711

712 **Fig. 6.** Metabolic functional prediction associated to quantitative profiles of (A) prevalent health-
713 associated bacteria OTUs and (B) linear discriminant analysis (LDA) combined effect size
714 (LEfSe) as bacterial species and associated microbial metabolic function biomarkers for healthy
715 or fat-metabolic disorder (denoted “unhealthy”) groups.

716 Microbial metabolic functions were estimated according to KEGG pathways. In (A), a different
717 color from nude to tangerine represents the level of quantitative microbial metabolic function
718 abundance from absence to the highest presence level (scale in vertical bar chart). In (B), a
719 numeric in front of KEGG name represents the KEGG pathway category: 1, metabolism; 2,
720 organismal systems; 3, diseases; 4, environmental information processing; 5, genetic information
721 processing; and 6, cellular processes. The LDA score > 3.0 was referred microbial metabolic
722 function markers (ANOVA Welch’s test, $P < 0.05$).

Figure 1

Schematic diagram of experimental design.




Figure 2

Relative percent gut microbiota compositions of aerobic and anaerobic transport groups at phylum, genus and species levels.

Color shades represent bacterial phyla: yellow (Firmicutes), blue (Bacteroidetes), red (Proteobacteria), grey (Fusobacteria), purple (Actinobacteria), white (Other), and pink (unclassified bacterial phyla). The OTUs where Mothur could not identify the genus (or species) names were denoted by small letters (o_ abbreviates order; f_, family; g_, genus and s_, species) to the deepest taxonomic names that could be identified; k_ abbreviated kingdom bacteria but unclassified phylum; and “Other” represented < 1% phylum (or genus, or species) OTUs.





Figure 3

Quantification of bacterial counts for (A) average total bacterial counts and (B) average strictly anaerobic and facultative anaerobic bacterial genera, comparing between aerobic and anaerobic sample transport groups.

Data were presented as average \pm SD. Statistical differences between groups were tested using Student's *t*-test ($P < 0.05$), and no statistical difference was found.

A



B




Figure 4

Scatter plots showing individual and mean range alpha diversity data at species OTUs of aerobic (filled circle) and anaerobic (empty square) sample transport groups, measured by (A) number of OTUs, (B) Chao1 richness, (C) inverse Simpson diversity, and (D)

Statistical differences between groups were tested using Student's *t*-test ($P < 0.05$), and no statistical difference was found: $P > 0.05$.




Figure 5

Non-metric multidimensional scaling (NMDS) constructed from Thetan coefficients displaying beta diversity among quantitative microbiota communities in aspects of (A) aerobic and anaerobic sample transport groups and (B-D) health and fat-metabolic disorder

In (A) and (B), AMOVA test was performed to determine statistical separation between designated groups ($P < 0.05$). In (C) and (D) showed the Pearson's correlations with health status parameters and the representing bacterial species OTUs, respectively. A vector direction and length represented the direction and strength of that parameter or OTU to the communities. A red arrow indicated a statistically significant correlation parameter ($P < 0.05$), and a black arrow indicated non-statistically significant correlation parameter ($P > 0.05$). In (C), GGT abbreviates gamma-glutamyl transferase; BMI, body mass index; stiffness, liver stiffness indicates the non-elasticity of the liver associated fat accumulation; TC, total cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TG, triglyceride; LDL, low-density lipoproteins; CAP, controlled attenuation parameter; and HDL, high-density lipoproteins.




Figure 6

Metabolic functional prediction associated to quantitative profiles of (A) prevalent health-associated bacteria OTUs and (B) linear discriminant analysis (LDA) combined effect size (LEfSe) as bacterial species and associated microbial metabolic function b

Microbial metabolic functions were estimated according to KEGG pathways. In (A), a different color from nude to tangerine represents the level of quantitative microbial metabolic function abundance from absence to the highest presence level (scale in vertical bar chart). In (B), a numeric in front of KEGG name represents the KEGG pathway category: 1, metabolism; 2, organismal systems; 3, diseases; 4, environmental information processing; 5, genetic information processing; and 6, cellular processes. The LDA score > 3.0 was referred microbial metabolic function markers (ANOVA Welch's test, $P < 0.05$).





Table 1 (on next page)

Average quality reads, OTUs and Good's coverage (%) at phylum, genus and species level.

For number of quality reads and OTUs, data were displayed in average \pm SD. Multiple t-tests were performed for OTUs and Good's coverages between aerobic and anaerobic sample transport groups and no statistical difference was determined ($P > 0.05$).

1 **Table 1.** Average quality reads, OTUs and Good's coverage (%) at phylum, genus and species
 2 level.
 3 For number of quality reads and OTUs, data were displayed in average \pm SD. Multiple *t*-tests
 4 were performed for OTUs and Good's coverages between aerobic and anaerobic sample
 5 transport groups and no statistical difference was determined ($P > 0.05$).

Groups	Quality sequences	Phylum		Genus		Species	
		OTUs	Good's coverage	OTUs	Good's coverage	OTUs	Good's coverage
All	40,587 \pm 24,139	6.80 \pm 1.22	100	72.05 \pm 10.76	99.82	101.38 \pm 16.05	99.72
Aerobic collection	53,116 \pm 24211	6.55 \pm 1.19	100	71.40 \pm 10.45	99.83	101.15 \pm 16.83	99.71
Anaerobic collection	28,059 \pm 16,715	7.05 \pm 1.23	100	72.70 \pm 11.29	99.81	101.60 \pm 15.67	99.72

6